News

After rejecting several bids, Shire has agreed to a merger with AbbVie valued at almost $55 billion.

AstraZeneca releases designs for its new Global R&D center and corporate headquarters in Cambridge, UK.

Baxter investigates root cause of cellulosic fibers and/or plastics in four lots of IV solutions.

Mylan set to acquire Abbott's non-US developed markets specialty and branded generics business in an all-stock transaction.

New AbbVie proposal results in discussion with Shire about possible $53 billion deal.

Baxter Healthcare has initiated a nationwide recall of more than 20,000 containers of a pre-mixed beta blocker due to the presence of particulate matter.

ASTM International develops Committee E62, a new technical committee focused on industrial biotechnology.

Puncture in container and overwrap cause leak in intravenous solution, leading to recall by Hospira.

Covance reports two senior-level appointments to it clinical development services scientific leadership team.

FDA clarifies GDUFA requirements in regards to abbreviated new drug applications and prior approval supplements.

New International Council on Biotechnology Associations advocates biotechnology growth.

The European Medicine Agency details the agency?s recommendations for drug-marketing authorizations for the first half of 2014.

FDA grants breakthrough therapy designation to Novartis chimeric antigen receptor therapy.

BioOutsource will expand its US presence, opening a new laboratory facility in Massachusetts to support the company's biosimilar and biosafety service offerings.

PlantForm and PharmaPraxis announce plans to develop six biopharmaceutical targets for the Brazilian market.

Genentech's $1.7 billion acquisition of Seargon Pharmaceutical includes portfolio of investigational next-generation oral selective estrogen receptor degraders.

Several groups, including pharmacies, call on FDA to preserve accepted International Nonproprietary Name conventions for biosimilars.

The collaboration will use Mersana Therapeutics Fleximer technology for antibody-drug conjugates.

European Medicines Agency clarifies advanced-therapy medicinal products classification.

FDA releases guidance documents and rules on requirements for compounding human drug products.

Merck funds Bionomics with $20 million to progress therapies for cognitive impairment caused by central nervous system disorders

Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.

GSK and Save the Children announce criteria for awards that recognize innovation in healthcare for the world"s poorest children.

Covance MarketPlace is designed to enable partnerships between the company's emerging biotechnology and established pharmaceutical clients.

Cytovance Biologics completes GMP manufacture of ARMO BioSciences' lead product.

Aesica Pharmaceuticals S.r.I. collaborates with QAD to meet China's Food and Drug Administration's shortened serialization deadline.

Rentschler plans to build two stainless-steel bioreactors to target market supply.

Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.